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Headache Questionnaire, and some additional items to
document medication and satisfaction with general ther-
apy. General information about management and preven-
tion of headache was offered to the 341 respondents suf-
fering from headache, as well as to physicians and
pharmacists. In a second survey, questionnaires were filled
out by the participants to record the impact of the pro-
gram.
RESULTS: Results from the first survey were reported by
Göbel et al. (Cephalalgia 17[1997]325). Of the 183 trace-
able initial respondents, 68.9% took part in the final sur-
vey: 29.1% of the participants reported an improvement
in health status; 43.1% stated fewer headaches; 38.9%
reported shorter headache attacks; 22.6% had better
knowledge to identify trigger factors; 21.0% reduced
their consumption of medication; and 41.9% learned an
active relaxation technique. Together with other exten-
sive healthcare measures initiated through the company,
there was a reduction of lost labor time due to illness.
CONCLUSION: It is possible to create a network between
employees, physicians, pharmacists, the sick fund, and the
pharmaceutical industry to successfully address the ques-
tion of headache management within a work-site environ-
ment. Unmet medical needs can be identified, and aware-
ness for intervention programs can be raised through
studies using general headache questionnaires. The infor-
mation of patients as well as physicians and pharmacists
reduced the burden of headache and improved the out-
comes of headache treatment. More collaborative efforts
to improve the unsatisfactory situation of headache pa-
tients and migraine patients are needed.
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The identification of cost components deriving from di-
rect and indirect consequences of disease is a fundamen-
tal step in conducting cost-effectiveness (CE) analysis. In
time-constrained efforts to collect CE data for inclusion
in a product’s commercial development dossier, little at-
tention is likely to be paid to fundamental research. Cou-
pled with other early research components, such as ex-
pert and/or patient interviews, a prior comprehensive
review of the literature can ensure a strong foundation on
which robust economic arguments could subsequently be
formulated.
OBJECTIVE: The objective of this research was to ex-
plore and define 1) cost drivers and 2) clinical endpoints
representing global treatment effectiveness in Parkinson’s
disease (PD).
METHODS: A review of the published literature in PD
was conducted, surveying elements including:
• Contemporary treatment options and costs;
• Clinical markers measuring progression;
• Indirect morbidity and related costs.
The geographic foci of the research were Germany and
the UK.
RESULTS: A global indicator of symptoms and compli-
cations of PD treatment is the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS); significant events represent-
ing complications and co-morbidity include prevalence
and severity of motor complications—dyskinesias, de-
pression, dementia, and postural imbalance—leading to
falls and other accidents. Hospitalization accounts for
50% to 90% of costs of PD care in Germany and the UK,
followed by medication costs. The main determinants of
hospitalization rates are disease stage, akinetic type of dis-
ease and presence of motor fluctuations in spite of, as well
as in relation to, therapy. 
CONCLUSIONS: In collecting economic data for PD
treatment, the definitive demonstration of CE must in-
clude improved long-term efficacy, safety, and reduced
rates of direct and indirect resource utilization—in partic-
ular, hospitalization.
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OBJECTIVE: Patient outcome measures of health utility
and functional status were used to assess sensitivity to
drug treatment and its relationship to PD severity.
BACKGROUND: A multicenter trial in seven countries
compared the safety, tolerance, and efficacy of pramipex-
ole (to 4.5 mg) and bromocriptine (to 30 mg) in advanced
PD. Patients (N  247, 80 pramipexole, 84 bromocrip-
tine, 83 placebo) were male and female, in- and out-
patients, 30 years and older, with advanced idiopathic
PD (stages II-IV Hoehn and Yahr [H&Y]), with motor
fluctuations characterized as end-of-dose phenomena.
Each received individually optimized dosages of levo-
dopa. (Guttman et al., “Double-blind comparison of pra-
mipexole and bromocriptine treatment with placebo in
advanced Parkinson’s disease,” [Neurology 49:Oct 1997,
1060–1065]).
METHODS: Patients were treated for up to 9 months, 11
days: 1) ascending dose up to 3 months, 2) maintenance
dose for approximately 6 months, and 3) decreasing dose
up to 11 days. Primary efficacy endpoints were: UPDRS
II—Activities of Daily Living (ADLs), averaged over “on”
and “off” periods, and UPDRS III—Motor Examination
during “on” periods. Secondary endpoints included the
EuroQoL visual analog scale (VAS) and Functional Status
